Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company
focused on improving cardiovascular health, today announced that
three Amarin-supported posters will be presented at the American
Diabetes Association 79th Scientific Sessions in San Francisco,
June 7 – 11, 2019. All three posters highlight important
findings regarding the challenges of current treatment options for
diabetes patients with cardiovascular risks. More than 30
million adults in the United States have diabetes, 10 million of
whom are considered at elevated risk for cardiovascular events,
despite being on cholesterol-management medicines.1,2
“We have learned through research that cholesterol and diabetes
management is not enough to effectively treat cardiovascular
disease in patients with diabetes and other risk factors,” said
Craig Granowitz, M.D., Ph.D., chief medical officer of
Amarin. “Cardiovascular disease is the No. 1 cause of death
in people with diabetes. We applaud the ADA for highlighting the
need to better understand and address increased cardiovascular risk
in patients with diabetes.”
Amarin-Supported Research to be Presented at the ADA
Scientific Sessions
Poster Presentations
Association Between Triglycerides and Residual Cardiovascular
(CVD) Risk in Patients with Type 2 Diabetes and Established CVD: An
Analysis of the BARI2D Trial, Abstract 1472-P, Embargoed Until
Saturday, June 8, 10 a.m. (Pacific Time).
- Neha J. Pagidipati, M.D., MPH; Ann Marie Navar, M.D., Ph.D.;
Hillary Mulder, M.S.; Daniel Wodjyla, M.S.; Sephy Philip, RPh,
PharmD; Craig Granowitz, M.D., Ph.D.; Eric D. Peterson, M.D.,
MPH.
Long-term Statin Persistence is Poor Among High-Risk Patients
with Baseline Diabetes: A Real-World Administrative Claims Analysis
of the Optum Research Database, Abstract 616-P, Embargoed Until
Saturday, June 8, 10 a.m. (Pacific Time),
- Peter P. Toth, M.D., Ph.D., Craig Granowitz, M.D., Ph.D.
Michael Hull, MS; Sephy Philip, RPh, PharmD.
Moderated Poster SessionEicosapentaenoic Acid
(EPA) Inhibits Human HDL Oxidation in a Concentration-Dependent
Manner at a Pharmacologic Dose in Vitro, Abstract 612-P; Embargoed
Until Saturday, June 8, 10 a.m. presented in poster sessions at 10
a.m. (Pacific Time) (New Concepts in Lipidology); Monday, June 10,
noon (Pacific Time) (General Poster Session)
- Samuel, C.R. Sheratt, B.S.; R. Preston Mason Ph.D.
About Amarin
Amarin Corporation plc. is a rapidly growing, innovative
pharmaceutical company focused on developing therapeutics to
improve cardiovascular health. Amarin’s product development program
leverages its extensive experience in polyunsaturated fatty acids
and lipid science. Vascepa (icosapent ethyl) is Amarin's first
FDA-approved drug and is available by prescription in the United
States, Lebanon and the United Arab Emirates. Amarin’s commercial
partners are pursuing additional regulatory approvals for Vascepa
in Canada, China and the Middle East. For more information about
Amarin, visit www.amarincorp.com.
About Cardiovascular Disease
Worldwide, cardiovascular disease (CVD) remains the No. 1 killer
of men and women. In the United States, CVD leads to one in every
three deaths – one death approximately every 38 seconds – with
annual treatment cost in excess of $500 billion.3,4
Multiple primary and secondary prevention trials have
shown a significant reduction of 25% to 35% in the risk
of cardiovascular events with statin therapy,
leaving significant persistent residual risk despite the
achievement of target LDL-C levels.5
Beyond the cardiovascular risk associated with LDL-C, genetic,
epidemiologic, clinical and real-world data suggest that patients
with elevated triglycerides (TG) (fats in the blood), and TG-rich
lipoproteins, are at increased risk for cardiovascular
disease. 6,7,8,9
Availability of Other Information About
Amarin
Investors and others should note that Amarin communicates with
its investors and the public using the company website
(www.amarincorp.com), the investor relations
website (investor.amarincorp.com), including but
not limited to investor presentations and investor FAQs, Securities
and Exchange Commission filings, press releases, public conference
calls and webcasts. The information that Amarin posts on these
channels and websites could be deemed to be material information.
As a result, Amarin encourages investors, the media, and others
interested in Amarin to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time to
time on Amarin’s investor relations website and may include social
media channels. The contents of Amarin’s website or these channels,
or any other website that may be accessed from its website or these
channels, shall not be deemed incorporated by reference in any
filing under the Securities Act of 1933.
References
1 Fan W, Philip S., Granowitz C, Toth P, Wong N. Prevalence
and Predictors of Residual Hypertriglyceridemia According to Statin
Use in US Adults with Diabetes. Presented at the American Diabetes
Association Scientific Sessions, June 22-26, 2018, Orlando,
Florida
2 Fan W, Philip S, Granowitz C, et al. Hypertriglyceridemia in
statin-treated US adults: the National Health and Nutrition
Examination Survey. J Clin Lipidol. 2019;13(1):100-108.
3 American Heart Association. 2018. Disease and Stroke
Statistics-2018 Update.
4 American Heart Association. 2017. Cardiovascular disease:
A costly burden for America projections through 2035.
5 Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for
adjunctive dyslipidemia therapy in hypertriglyceridemia
management. J Am Coll Cardiol. 2018;72(3):330-343.
6 Budoff M. Triglycerides and triglyceride-rich
lipoproteins in the causal pathway of cardiovascular
disease. Am J Cardiol. 2016; 118:138-145.
7 Toth PP, Granowitz C, Hull M, et al. High triglycerides
are associated with increased cardiovascular events, medical costs,
and resource use: A real-world administrative claims analysis of
statin-treated patients with high residual cardiovascular
risk. J Am Heart Assoc. 2018;7(15): e008740.
8 Nordestgaard BG. Triglyceride-rich lipoproteins and
atherosclerotic cardiovascular disease - New insights from
epidemiology, genetics, and biology. Circ Res. 2016;
118:547-563.
9 Nordestgaard BG, Varbo A. Triglycerides and
cardiovascular disease. Lancet. 2014; 384:626–635.
Amarin Contact Information
Media Inquiries: Gwen Fisher
Corporate Communications Amarin Corporation plc In U.S.: +1
(908) 325-0735 pr@amarincorp.com
Investor Inquiries: Elisabeth Schwartz Investor
Relations Amarin Corporation plc In U.S.: +1 (908)
719-1315 investor.relations@amarincorp.com
Lee M. Stern Trout Group In U.S.: +1 (646)
378-2992 lstern@troutgroup.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2023 to Mar 2024